| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 32,065 | 32,090 | 15:56 | |
| 0,000 | 0,000 | 15:52 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 31,990 | 635 | |||
| 31,985 | 1.081 | |||
| 31,980 | 635 | |||
| 31,975 | 636 | |||
| 31,970 | 635 | |||
| 31,965 | 635 | |||
| 31,960 | 1.035 | |||
| 31,955 | 636 | |||
| 31,950 | 1.123 | |||
| 31,945 | 651 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/nov.htm [/URL] | ||||
| 111 | 31,920 | |||
| 500 | 31,915 | |||
| 1.197 | 31,910 | |||
| 1.096 | 31,905 | |||
| 1.302 | 31,900 | |||
| 910 | 31,895 | |||
| 1.683 | 31,890 | |||
| 1.330 | 31,885 | |||
| 16.637 | 31,880 | |||
| 608 | 31,875 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 25.374 | 0,304 | 7.702 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 15:41:20 | 31,930 | 140 |
| 15:41:05 | 31,920 | 1 |
| 15:41:05 | 31,920 | 3 |
| 15:40:58 | 31,900 | 1 |
| 15:39:59 | 31,900 | 437 |
| 15:39:36 | 31,920 | 260 |
| 15:39:23 | 31,920 | 24 |
| 15:39:23 | 31,920 | 413 |
| 15:39:23 | 31,900 | 3.487 |
| 15:39:23 | 31,905 | 4 |
| 15:39:23 | 31,910 | 105 |
| 15:39:23 | 31,915 | 1 |
| 15:39:23 | 31,920 | 360 |
| 15:39:23 | 31,925 | 3 |
| 15:39:16 | 31,930 | 6 |
| 15:39:16 | 31,930 | 23 |
| 15:39:16 | 31,930 | 271 |
| 15:39:16 | 31,930 | 100 |
| 15:39:04 | 31,930 | 1 |
| 15:38:50 | 31,960 | 400 |
| Tagesumsatz Xetra | -0,230 -0,72 % | 364.218 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:23 | Vivtex erhält von Novo Nordisk bis zu 2,1 Milliarden Dollar | 20 | punkt4.info | ||
| 14:59 | Lilly says orforglipron tops Wegovy pill in diabetes trial | 40 | pharmaphorum | ||
| 13:38 | NOVO NORDISK A/S: Stabilität im Übergang | 44 | Maximilian Berger | ||
| 13:21 | Novo Nordisk and Vivtex partner in deal worth up to $2.1bn | 22 | PMLiVE | ||
| NOVO NORDISK Aktie jetzt für 0€ handeln | |||||
| 11:10 | Novo Nordisk-Aktie: Kurssturz auf unter 30 Euro möglich | 799 | sharedeals.de | Die Aktie von Novo Nordisk galt lange als Inbegriff eines sicheren Wachstumsinvestments und als einer der größten Gewinner des globalen Pharma-Booms. Doch nach einer Serie enttäuschender Nachrichten... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 10:00 | Hikma Pharma FY25 Earnings Rise; Launches $250 Mln Buyback, Guides FY26; Shares Plunge | AFX News | LONDON (dpa-AFX) - Hikma Pharmaceuticals PLC (HIK.L), on Thursday reported higher profit for the full year 2025, driven by revenue growth and improved core performance.For the full year 2025... ► Artikel lesen | |
| 09:54 | GSK's NDA For Bepirovirsen Accepted In Japan For Chronic Hepatitis B | AFX News | LONDON (dpa-AFX) - GSK plc (GSK) on Thursday said Japan's Ministry of Health, Labour and Welfare has accepted a new drug application for bepirovirsen for the treatment of adults with chronic... ► Artikel lesen | |
| 12:36 | Compass Pathfinder Limited: Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants | Business Wire | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were... ► Artikel lesen | |
| 13:36 | Lilly's Orforglipron Outperforms Semaglutide In Blood Sugar And Weight Reduction In Phase 3 Study | AFX News | INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) on Thursday reported positive results from its Phase 3 ACHIEVE-3 trial evaluating orforglipron in adults with type 2 diabetes inadequately... ► Artikel lesen | |
| 13:10 | Boehringer Ingelheim Limited: Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics | GlobeNewswire (Europe) | The preclinical, small molecule program offers a potential first-in-class, oral, precision immunometabolic approach to modulating disease-driving immune cellsDeal includes upfront and milestone payments... ► Artikel lesen |